INTRODUCTION
Nilotinib (Tasigna; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is a selective inhibitor of BCR-ABL and a more potent inhibitor than imatinib in vitro.
1 Based on data from the Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients (ENESTnd) phase 3 trial in which nilotinib demonstrated superiority over imatinib, nilotinib has been widely approved throughout the world for the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph þ ) chronic myeloid leukemia in chronic phase (CML-CP). 2 ENESTnd is an international, open-label, randomized study comparing the efficacy and safety of nilotinib 300 and 400 mg twice daily and imatinib 400 mg once daily in patients with newly diagnosed Ph þ CML-CP. 3 In previous reports after 1 and 2 years of treatment, nilotinib demonstrated superior efficacy to imatinib with significantly faster and higher rates of complete cytogenetic response (CCyR), major molecular response (MMR), deeper molecular response of BCR-ABLp0.01% expressed on the international scale (BCR-ABL IS ; MR 4 ) and BCR-ABL IS p0.0032% (MR 4.5 ). 3, 4 Moreover, there were significantly lower rates of progression to accelerated phase/blast crisis (AP/BC) and fewer CML-related deaths in the nilotinib arms when compared with imatinib. The International Randomized Study of Interferon vs STI571 trial showed that most disease progression events on imatinib occurred within the first 3 years of treatment, indicating that this represents an important milestone. 5 This report presents the updated results of the ENESTnd trial for patients within this important 3-year time frame.
MATERIALS AND METHODS

Patients, study design and treatments
Study criteria for eligibility have been extensively described previously. 3, 4 Written informed consent was obtained from each patient, and the study was conducted according to the ethical principles of the Declaration of Helsinki. As described previously, patients X18 years of age were eligible for this study if they had newly diagnosed Ph þ CML-CP within the previous 6 months. A total of 846 patientsX18 years of age, with newly diagnosed Ph þ CML-CP within the previous 6 months, were randomized to nilotinib 300 mg twice daily (n ¼ 282), nilotinib 400 mg twice daily (n ¼ 281) or imatinib 400 mg once daily (n ¼ 283). 3, 4 Randomization was stratified according to Sokal risk score at the time of diagnosis. 3, 4 The study was registered at ClinicalTrials.gov (NCT00471497).
As described previously, 3, 4 patients in the imatinib arm could be doseescalated to 400 mg twice daily if they had a suboptimal response per investigator assessment and could receive nilotinib as part of a separate extension study in the case of treatment failure. 6 In contrast, nilotinibtreated patients could not dose-escalate, although patients in the nilotinib 300 mg twice-daily arm could discontinue the study and also enter the extension study to receive nilotinib 400 mg twice daily for cases of 1 suboptimal response or treatment failure, and patients in the nilotinib 400 mg twice-daily arm could only enter the extension study to receive imatinib 400 mg twice daily for treatment failure.
Using a central laboratory in Portland, OR, USA (MolecularMD), molecular response was assessed by real-time quantitative PCR at baseline, monthly (1 month ¼ 28 days) for 3 months and every 3 months thereafter. At baseline and at 6, 12, 18 and 24 months, conventional bone marrow cytogenetic analyses were performed on core treatment. After 24 months on core treatment, only patients without MMR or with any clinical indication of progressive disease (that is, additional chromosomal abnormalities on previous bone marrow assessments, increase in BCR-ABL transcripts of at least fivefold) had a cytogenetic assessment. Progression to AP/BC while patients were on treatment was assessed based on hematological and cytogenetic data. Progression events were also reported solely based on the investigators' assessments every 3 months after discontinuation of treatment up to 10 years from randomization and were not censored at the time at which patients received subsequent therapy after discontinuation of treatment in the ENESTnd study. Also, overall survival (OS) information was collected every 3 months up to 10 years from randomization, including follow-up after treatment discontinuation. Only about 5% of patients in each arm were unavailable for these long-term assessments after discontinuation.
Endpoints
As reported, the MMR rate at 1 year was the primary efficacy endpoint. 3, 4 MMR was defined as BCR-ABL IS p0.1% by real-time quantitative-PCR in peripheral blood. MMR was assessed conservatively based on evaluation of b3a2 and b2a2 BCR-ABL transcripts. Patients with atypical transcripts or unavailable or missing samples were considered as nonresponders. Other endpoints included the rate of MMR, MR 4 and MR 4.5 by 3 years; time to progression to AP/BC (defined as progression to AP/BC or death due to CML, whichever occurred first), including events on treatment and events after discontinuation of study treatment; progression-free survival (progression defined as progression to AP/BC or death due to any cause while on treatment); event-free survival (event defined as loss of response (any of complete hematological response, partial response or CCyR), progression to AP/BC or death due to any cause while on treatment); and OS (defined as freedom from death owing to any cause while on treatment or during follow-up after discontinuation of treatment).
Statistical analysis
All efficacy results are reported for the intention-to-treat population; patients were analyzed according to the treatment to which they were randomized. Response rates were provided by specific time points. Patients who had achieved a response at or before a specific time point were considered as responders by that time point. Therefore, this response rate represents the best response rate up to that specific time point. A twosided stratified Cochran-Mantel-Haenszel test, based on the randomization strata, was used to test the statistical significance of differences in response rates. Time-to-response variables (MMR, MR 4 and MR 4.5 ) were also presented by cumulative incidence graphs, which were displayed by an increasing step function. This curve increased each time (after randomization) at which a new responder was recorded and thus increased up to the best recorded response rate. Long-term outcomesincluding event-free survival, progression-free survival, time to progression to AP/BC and OS-were analyzed using the Kaplan-Meier method. All time-to-event variables were compared between groups with the stratified log-rank test on the basis of the randomization strata. Hazard ratios (HRs) and 95% confidence intervals were derived from a Cox model stratified by the randomization strata. For all secondary endpoints reported here, P-values are provided for descriptive purposes and are not adjusted for multiple comparisons. Safety analyses are reported for the safety population, which included all patients who received at least one dose of study treatment.
RESULTS
Patients and treatments
The data cutoff for this analysis was 27 July 2011, when all patients had either completed 36 months (1 month ¼ 28 days) of treatment or discontinued early. At the time of data cutoff, the median time on treatment (from start of treatment to discontinuation of study treatment) was 36.4 (range, 0.1-46.7) months on nilotinib 300 mg twice daily, 36.6 (range, 0.2-46.0) months on nilotinib 400 mg twice daily and 35.5 (range, 0.0-46.5) months on imatinib. The median time on study (from randomization to last available date on study, including follow-up after discontinuation of treatment) was B37.6 months across all three arms. The median (25th-75th percentile) dose intensity was 594 (548-600) mg/day in the nilotinib 300 mg twice-daily arm and 778 (594-799) mg/day in the nilotinib 400 mg twice-daily arm. In the imatinib arm, the median dose intensity was 400 (395-470) mg/day.
By the time of data cutoff, B95% of patients in each treatment arm were still in active follow-up (that is, either remained on treatment or remained in follow-up after discontinuation of study treatment) or completed follow-up (that is, died on treatment or during follow-up after discontinuation of treatment). Overall, 29.1%, 26.3% and 38.2% of patients in the nilotinib 300 mg twicedaily, nilotinib 400 mg twice-daily and imatinib arms, respectively, discontinued core treatment by the time of data cutoff ( Table 1) . Discontinuations due to adverse events or laboratory abnormalities were observed in 9.9%, 14.2% and 11.0% of patients in the nilotinib 300 mg twice-daily, nilotinib 400 mg twice-daily and imatinib arms, respectively. More patients in the imatinib arm (20.1%) discontinued treatment due to disease progression, treatment failure or suboptimal response compared with the nilotinib 300 mg twice-daily arm (9.9%) or the nilotinib 400 mg twice-daily arm (5.3%).
Efficacy
Consistent with the results at 1 and 2 years of follow-up, the MMR rate by 3 years ( Figure 1 ) was significantly higher for nilotinib 300 mg twice daily (73%, Po0.0001) and nilotinib 400 mg twice daily (70%, Po0.0001) compared with imatinib (53%). The rate of MMR at 3 years in patients with evaluable samples was also higher for nilotinib compared with imatinib, with 165 of 195 (85%) patients with evaluable samples achieving MMR in the nilotinib 300 mg twice-daily arm, 161 of 203 patients (79%) in the nilotinib 400 mg twice-daily arm and 109 of 171 (64%) patients in the Patients were either on study drug or in follow-up after discontinuation of study treatment. Patients with suboptimal response or treatment failure were allowed to discontinue core study and enter into extension study. Includes abnormal test procedure result(s), condition no longer requires study drug, consent withdrawn, loss to follow-up, administrative problems and protocol deviation.
imatinib arm. Overall, 34 patients had a confirmed loss of MMR at any time (nine patients in the nilotinib 300 mg twice-daily arm, 11 patients in the nilotinib 400 mg twice-daily arm and 14 patients in the imatinib arm). Confirmed loss of MMR was transient in some patients: 6 of 9 patients in the nilotinib 300 mg twice-daily arm, 5 of 11 patients in the nilotinib 400 mg twice-daily arm and 6 of 14 patients in the imatinib arm regained MMR after losing it.
Similarly, the rate of MR 4 by 3 years was significantly higher for nilotinib 300 mg twice daily compared with imatinib (50% vs 26%, Po0.0001) and nilotinib 400 mg twice daily compared with imatinib (44% vs 26%, Po0.0001; Figure 2a) . Also, the achievement of MR 4.5 by 3 years was significantly higher for nilotinib 300 mg twice daily compared with imatinib (32% vs 15%, Po0.0001) and for nilotinib 400 mg twice daily compared with imatinib (28% vs 15%, P ¼ 0.0003; Figure 2b) . Furthermore, the difference in the rates of MR 4 and MR 4.5 increased over time between the nilotinib and imatinib arms (Figures 2a and b) . The difference in the rate of MR 4 increased by approximately twofold between the nilotinib 300 mg twice-daily and imatinib arms, from 14% by 1 year to 24% by 3 years. Similarly, the difference in the rate of MR 4.5 increased by approximately twofold between the nilotinib 300 mg twice-daily and imatinib arms from 10% by 1 year to 17% by 3 years.
Molecular responses were also deeper in patients who achieved MMR on nilotinib compared with patients who achieved MMR on imatinib. Of the 207 patients who achieved MMR at any time on nilotinib 300 mg twice daily, 70% achieved a response of MR 4 Table 2 ). Note that after the 2-year visit, cytogenetic assessments were not required for all patients; hence, no update on CCyR rates is provided.
There were no new cases of progression to AP/BC on core treatment with or without clonal evolution since the 2-year analysis. Overall, by the 3-year data cutoff, 17 patients had progressed to AP/BC on core treatment (excluding clonal evolution): 2 (0.7%) in the nilotinib 300 mg twice-daily arm, 3 (1.1%) in the nilotinib 400 mg twice-daily arm and 12 (4.2%) in the imatinib arm. Patients receiving either dose of nilotinib had a significantly lower probability of progression to AP/BC on treatment than patients receiving imatinib (HR ¼ 0.16 and P ¼ 0.0059 between nilotinib 300 mg twice daily and imatinib, HR ¼ 0.25 and P ¼ 0.0185 between nilotinib 400 mg twice daily and imatinib (Table 3) ). 
When clonal evolution was considered as a criterion for progression to AP, two additional patients in the nilotinib 400 mg twice-daily arm and five additional patients in the imatinib arm had progression events. Overall, by the 3-year data cutoff, 24 patients progressed to AP/BC on treatment (including clonal evolution): 2 (0.7%) in the nilotinib 300 mg twice-daily arm, 5 (1.8%) in the nilotinib 400 mg twice-daily arm and 17 (6.0%) in the imatinib arm. Patients receiving either dose of nilotinib had a significantly lower probability of progression to AP/BC on treatment than patients receiving imatinib, when clonal evolution was considered as a criterion for progression (HR ¼ 0.11 and P ¼ 0.0003 between nilotinib 300 mg twice daily and imatinib, HR ¼ 0.28 and P ¼ 0.0085 between nilotinib 400 mg twice daily and imatinib (Table 3) ).
Since the 2-year analysis, 4 two new cases of progression to AP/BC (one in the nilotinib 400 mg twice-daily arm and one in the imatinib arm) were observed after discontinuation of study treatment. Overall, by the 3-year data cutoff, 34 patients progressed to AP/BC on treatment or during follow-up after discontinuation of treatment: 9 (3.2%) in the nilotinib 300 mg twice-daily arm, 6 (2.1%) in the nilotinib 400 mg twice-daily arm and 19 (6.7%) in the imatinib arm. When considering progression events occurring on treatment or during follow-up after discontinuation of treatment, the advantage on both nilotinib arms over imatinib in preventing progression remained significant (HR ¼ 0.46 and P ¼ 0.0496 between nilotinib 300 mg twice daily and imatinib, HR ¼ 0.31 and P ¼ 0.0076 between nilotinib 400 mg twice daily and imatinib).
The long-term outcome of patients who progressed to AP/BC was poor. The median OS of patients after progression to AP/BC in any treatment arm of ENESTnd was only 10.5 months (Figure 3) .
Estimated 3-year rates of event-free survival, progression-free survival and OS were all higher for both nilotinib arms compared with the imatinib arm (Table 3) . Since the 2-year analysis, three new event-free survival events were observed on treatment, one in each treatment arm (one patient died in the nilotinib 300 mg twice-daily arm, one patient died in the imatinib arm and one patient had a loss of CCyR in the nilotinib 400 mg twice-daily arm). There were two new progression-free survival events observed on treatment: the death events described for the nilotinib 300 mg twice-daily and imatinib arms.
The estimated rates of OS at 3 years were 95.1% for nilotinib 300 mg twice daily, 97.0% for nilotinib 400 mg twice daily and 94.0% for imatinib. In all, 12 new deaths were reported since the 2-year analysis: 4 in the nilotinib 300 mg twice-daily arm (1 on treatment (cardiogenic shock) and 3 after treatment discontinuation (multi-organ failure, ovarian epithelial cancer and 1 unknown cause)), 2 in the nilotinib 400 mg twice-daily arm (both after treatment discontinuation (1 CML-related and 1 metastatic neoplasm)) and 6 in the imatinib arm (1 on treatment (bronchopneumonia) and 5 after treatment discontinuation (4 CML-related and one pneumonia)). Of the 38 total deaths on study, 23 were considered CML-related. In all, 20 of these 23 deaths were considered CML-related as they were attributed to progressive disease by the investigator. In addition, three patients in the imatinib arm progressed to AP/BC and then died (one patient each due to sepsis, pneumonia and septic shock). These three deaths were also considered CML-related.
When only CML-related deaths were considered, OS was significantly higher in the nilotinib 300 mg twice-daily and nilotinib 400 mg twice-daily arms vs imatinib. The estimated rates of OS for CML-related deaths at 3 years were 98.1%, 98.5% and 95.2% in the nilotinib 300 mg twice-daily, nilotinib 400 mg twice-daily and imatinib arms, respectively (HR ¼ 0.35 and P ¼ 0.0356 between nilotinib 300 mg twice daily and imatinib, HR ¼ 0.28 and P ¼ 0.0159 between nilotinib 400 mg twice daily and imatinib).
Safety
The safety data are consistent with the previous report at 2 years, and a minimal change in the safety profile was observed since the 2-year analysis. Table 4 summarizes the newly occurring or worsening hematological and biochemical abnormalities, together with clinically important adverse events at 2 and 3 years. One patient experienced newly occurring grade 3/4 neutropenia and another patient experienced thrombocytopenia (both on imatinib), and five additional patients experienced grade 3/4 anemia (one on nilotinib 300 mg twice daily, two on nilotinib 400 mg twice daily and two on imatinib) since the 2-year analysis. Four additional patients experienced newly occurring grade 3/4 lipase increase (one each on both nilotinib arms and two on imatinib), two new cases of grade 3/4 hyperglycemia on nilotinib 400 mg twice daily, one new case of grade 3/4 bilirubin increase on nilotinib 300 mg twice daily and one new case of grade 3/4 aspartate transaminase increase on imatinib since the 2-year analysis.
During their time on treatment, seven patients on nilotinib (four on nilotinib 300 mg twice daily and three on nilotinib 400 mg twice daily) had a peripheral arterial occlusive disease (PAOD) In all, 3 of the 11 patients with newly appearing IHD had an event onset date before the 2-year analysis cutoff. Two of these events appeared newly with this data cutoff as a result of a MedDRA version change, and the third event was reported late by the investigator and therefore was not included at the 2-year cutoff.
b One patient in the nilotinib 300 mg twice-daily arm and two patients in the nilotinib 400 mg twice-daily arm who were reported with PAOD during the 2-year analysis were not included in the 3-year analysis because of changes in the grouped AE search algorithm (the terms 'arteriosclerosis' and 'poor peripheral circulation' were removed from the PAOD search terms used for the 3-year analysis).
event; there were no PAOD events on the imatinib arm. Two of these seven patients had PAOD events that occurred between 2 and 3 years, and both occurred in the nilotinib 400 mg twicedaily arm. No patient discontinued the study as a result of PAOD, and pre-existing risk factors for PAOD were identified at study entry in six of these seven patients (85.7%). Adverse events related to ischemic heart disease (IHD) were more frequent with nilotinib than with imatinib: 9 patients (3.2%) in the nilotinib 300 mg twicedaily arm, 11 patients (4.0%) in the nilotinib 400 mg twice-daily arm and 3 patients (1.1%) in the imatinib arm. In all, 11 of these 23 patients had IHD events that occurred between 2 and 3 years on study (4 in the nilotinib 300 mg twice-daily arm, 5 in the nilotinib 400 mg twice-daily arm and 2 in the imatinib arm). Three patients in the nilotinib 400 mg twice-daily arm discontinued study drug as a result of an IHD event. No patient in either nilotinib arm had a QTcFX500 ms or LVEFp45% during treatment at any time.
DISCUSSION
These results from the ENESTnd study following a minimum follow-up period of 3 years confirm the superiority of nilotinib compared with imatinib for the treatment of patients with newly diagnosed Ph þ CML-CP. Nilotinib induces superior rates of MMR, MR 4 and MR 4.5 compared with imatinib. Rates of progression to AP or BC are significantly lower among patients treated with nilotinib compared with those treated with imatinib. Also, the risk of CMLrelated death was lower for patients treated with nilotinib compared with patients treated with imatinib. The incidence of IHD was higher on nilotinib than on imatinib, and several new cases of IHD were observed between 2 and 3 years. PAOD was infrequent on nilotinib and occurred primarily in patients with preexisting risk factors. The estimated rate of OS at 3 years was numerically higher for nilotinib compared with imatinib, but the differences were not statistically significant. All patients, including those who were discontinued from the study, will continue to be followed up for survival every 3 months for 10 years.
This 3-year follow-up is especially important to the CML community, because the previous landmark International Randomized Study of Interferon vs STI571 study with imatinib indicated that most disease progression events occurred within the first 3 years of treatment. 5 Results from ENESTnd demonstrate that, compared with imatinib, patients treated with nilotinib had lower rates of progression throughout this entire 3-year period. Importantly, the OS of patients who progressed to AP or BC was poor, with a median OS time after progression of only 10.5 months. Interestingly, the median OS of patients following progression in ENESTnd is very similar to that from the International Randomized Study of Interferon vs STI571 trial (Figure 3) , showing that current therapies are relatively ineffective at extending life once CML progresses beyond the chronic phase. These data suggest that treatment with first-line nilotinib is a better clinical strategy than starting with imatinib followed by switching to nilotinib for inadequate responses. Results of randomized clinical studies switching patients from imatinib to nilotinib would be required before this could be validated in the community setting.
Importantly, nilotinib demonstrated significantly higher rates of MMR, MR 4 and MR 4.5 across all Sokal risk groups. In a subanalysis of older patients (X65 years) in ENESTnd with 2 years of follow-up, nilotinib demonstrated high rates of CCyR and MMR similar to those in younger patients and was superior to imatinib. 7 Thus, it is expected that more patients will achieve the deepest levels of response, perhaps including sustained undetectable levels of disease, on nilotinib than on imatinib. 8 This is significant because an important goal of CML therapy has recently shifted to treatment cessation studies for patients in longterm complete molecular remission. These carefully monitored studies typically require deep molecular responses (that is, a minimum of MR 4.5 sustained forX2 years) as a prerequisite for discontinuation of tyrosine kinase inhibitor therapy. [9] [10] [11] [12] [13] Therefore, there is a need to increase the number of patients with the deepest levels of response, and results from ENESTnd suggest that first-line nilotinib therapy may increase the number of patients eligible for treatment cessation. Taken together, these data suggest that nilotinib is superior to imatinib for the treatment of patients with newly diagnosed Ph þ CML-CP and should be preferred as the first-line therapeutic option for this population.
